Items tagged with Treatment
Biomarker for individualized therapy durations in patients with TB (post)
In patients with tuberculosis (TB), a host 22-gene RNA-based model has been identified that may be predictive of individual treatment durations with antimicrobial therapy, potentially leading to a substantially shorter treatment durations for many patients. This was among the results of an analysis recently published in the European Respiratory Journal.
A survivor’s take: Why India must ensure a shorter oral regimen to treat drug-resistant TB (post)
Despite the emergence of new medicines to treat the disease, the country’s existing health system offers little help in reducing the suffering of patients.
Five developments in paediatric TB (post)
The screening, diagnosis, and treatment of tuberculosis (TB) in children remain far from optimal – and in many respects lag behind what can be done for adults.
Optimal dosing of rifampicin/isoniazid/pyrazinamide in children with TB (post)
Treatment with an updated fixed-dose combination (FDC) of rifampicin/isoniazid/ pyrazinamide may decrease the risk for insufficient exposure to rifampicin among children with tuberculosis (TB) infection, according to results of a prospective study published in Clinical Infectious Diseases.
ACTG announces initiation of CLO-FAST, its first trial evaluating a three-month TB treatment (post)
10 November 2021: The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5362 (CLO-FAST), a clinical trial studying a three-month clofazimine- and high-dose rifapentine-containing treatment regimen for people with drug-susceptible tuberculosis (TB). This is the first TB regimen based on preclinical evidence of effectiveness that is less than four-months long to be studied in a clinical trial. A5362 will evaluate the potential efficacy of clofazimine when combined with treatments that have been proven to be effective against TB.
Global individual patient data platform for drug-resistant TB treatment (post)
In order to increase the knowledge base for normative guidance on optimal treatment modalities for drug-resistant tuberculosis (DR-TB), WHO is announcing a publicly accessible global individual patient data (IPD) platform for drug-resistant tuberculosis treatment (DR-TB-IPD). This will be a secure but accessible platform containing outcomes of over 10,000 drug-resistant TB patients as the starting point and expanding this with data received in response to a recent public call for data.
Improved TB tests and treatments are vital to overcoming drug resistance (post)
In the face of the COVID-19 pandemic, tuberculosis mortality has started to increase for the first time in a decade. In 2020 alone, more than 1.5 million people died from TB. Every year, about half a million people develop a drug-resistant form of TB (DR-TB).
TaBriX, University of Manchester and TB Alliance to develop drug-resistant TB treatments (post)
TaBriX is a new spin-out company from The University of Manchester (UoM) with the mission to create novel anti-virulence drugs to fight difficult-to-treat infections. TaBriX’s initial focus is on the treatment of drug-resistant TB.
With TB resurgent after two years of COVID-19-inspired neglect, TB Alliance is awarded USAID funding to develop new treatments (post)
NEW YORK, NY (20 January 2022) — Today, TB Alliance announced that it has received funding from the United States Agency for International Development (USAID) to jumpstart the search for new tuberculosis (TB) treatments, optimize current treatments so that they can treat children as well as adults, and strengthen health systems in high-TB-burden countries so that all people with TB disease can get treated and quickly return to full health. The funding of up to US$30 million will be administered over a period of 5 years.
Frequency of adverse events in patients with multidrug-resistant TB (post)
Among patients with multidrug-resistant tuberculosis (MDR-TB), adverse events related to treatment with linezolid and injectable drugs were found to be more common compared with those related to bedaquiline and delamanid, according to a multicenter, prospective observational study published in Clinical Infectious Diseases.
Page 61 of 108 · Total posts: 0
←First 60 61 62 Last→